YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

KC firm lands $45M+ drug licensing deal

Posted online
Leawood, Kan.-based Aratana Therapeutics Inc. (Nasdaq: PETX) has sold licensing rights for its first Food and Drug Administration-approved drug to a division of pharmaceutical giant Eli Lilly and Co. (NYSE: LLY).

Greenfield, Ind.-based Elanco – Eli Lilly’s animal-health division – now has the rights to develop, manufacture, market and commercialize Galliprant globally under terms of the deal.

Aratana Therapeutics is slated to receive $45 million up front, additional payments for hitting certain development gates, regulatory and sales milestones up to $83 million and co-promotion fees and royalty payments, the Kansas City Business Journal reports, citing a U.S. Securities and Exchange Commission filing.

Read more from the Kansas City Business Journal.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences